top
Please input keywords
Development History
Committed to innovation with partners
2009
2011
2014
2013
2015
2016
2018
2019
2020
2021
2009
Our Company was established in Beijing, China as our headquarters to commence research and development of biotechnology in the China
2011
Developed ESC/HR-based gene editing technology platform and delivered our gene editing services to our first customer
2014
Developed CRISPR/EGE-based gene editing technology, which enables simultaneous gene knock-in of two genes in rats Developed the severe immunodeficient B-NDG™ mice and developed a series of immune checkpoint humanized mice based on the genetic background of C57BL/6
2013
Completed the series A round financing and raised an aggregate amount of approximately RMB35 million
2015
Established a comprehensive pharmacology service platform, covering cell-based functional assays, pharmacokinetic assays and drug metabolism assays Completed the series B round financing and raised an aggregate amount of approximately RMB40 million
2016
Haimen Animal Center began operations and earned the full-qualification AAALAC accreditation, building an international high-standard animal center Established an evidence-based in vivo antibody discovery platform Eucure (Beijing) was established to engage in pre-clinical and clinical development of drug candidates that are derived from our Group’s antibody discovery platform, including YH001 and YH003 Completed the series B+ round financing in the form of convertible loans of an aggregate amount of approximately RMB21.7 million, which was subsequently converted into equity in our Company in February 2018
2018
BIOCYTOGEN BOSTON CORP was incorporated through which we expanded our operations in the U.S. Completed the series C round financing and raised an aggregate amount of approximately RMB260 million
2019
Developed technology for megabase-scale chromosomal editing and released RenMab Mice, a fully human antibody mouse model Obtained approval for commencing Phase I clinical trials of YH001 in patients with advanced solid tumors in the U.S. Completed the series D round financing and raised an aggregate amount of approximately RMB500 million
2020
Completed first patient screening for Phase I clinical studies of YH001, YH002 and YH003 in Australia Launched Project Integrum, a large-scale in vivo antibody discovery program Completed the series D+ round financing and raised an aggregate amount of approximately RMB850 million
2021
Completed first patient screening for Phase I clinical study of YH001 and obtained approval to initiate Phase I clinical trial of YH003 in the PRC Completed Phase I clinical trial of YH003, entered Phase II clinical study of YH003 in Australia, and obtained approvals to commence Phase II clinical trials for YH001 and YH003 in the U.S. and Phase I clinical trial of YH004 in Australia. Completed the cross-over round financing and raised an aggregate amount of approximately RMB311.0 million